JP2012533630A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012533630A5 JP2012533630A5 JP2012521700A JP2012521700A JP2012533630A5 JP 2012533630 A5 JP2012533630 A5 JP 2012533630A5 JP 2012521700 A JP2012521700 A JP 2012521700A JP 2012521700 A JP2012521700 A JP 2012521700A JP 2012533630 A5 JP2012533630 A5 JP 2012533630A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- substituted
- acceptable salt
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HZXBVTUZHCBOSI-UHFFFAOYSA-N C(COC1)C1OC1CCCCC1 Chemical compound C(COC1)C1OC1CCCCC1 HZXBVTUZHCBOSI-UHFFFAOYSA-N 0.000 description 2
- 0 C[C@](CC1)CC[C@]1C(*c1c(C(O)=O)[s]c(C#CC(C)(C)COC2CCOCC2)c1)=O Chemical compound C[C@](CC1)CC[C@]1C(*c1c(C(O)=O)[s]c(C#CC(C)(C)COC2CCOCC2)c1)=O 0.000 description 2
- STYZOEAXSMEXGV-PDPKZZNXSA-N CC(CC1)CCC1C(N(CCOc1ncccc1)c1c(C(O)=O)[s]c(C#CC(C)(C)Cc2nc(S[C@H](CC3)CC[C@@H]3N(C([C@H]3CC[C@H](C)CC3)=O)c3c(C(O)=O)[s]c(C#CC(C)(C)C)c3)ncc2)c1)=O Chemical compound CC(CC1)CCC1C(N(CCOc1ncccc1)c1c(C(O)=O)[s]c(C#CC(C)(C)Cc2nc(S[C@H](CC3)CC[C@@H]3N(C([C@H]3CC[C@H](C)CC3)=O)c3c(C(O)=O)[s]c(C#CC(C)(C)C)c3)ncc2)c1)=O STYZOEAXSMEXGV-PDPKZZNXSA-N 0.000 description 1
- KFVRDWIDIHRPMV-RZZSZECMSA-N CC(CC1)CCC1C(N([C@H](CC1)CC[C@@H]1Oc1nccc(C(NC2CCN(C)CC2)=O)c1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound CC(CC1)CCC1C(N([C@H](CC1)CC[C@@H]1Oc1nccc(C(NC2CCN(C)CC2)=O)c1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O KFVRDWIDIHRPMV-RZZSZECMSA-N 0.000 description 1
- HQJJNPLFWPONOJ-AULMGXOSSA-N CC(CC1)CCC1C(N([C@H](CC1)CC[C@H]1Oc1cc(CN(C)C)ccn1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound CC(CC1)CCC1C(N([C@H](CC1)CC[C@H]1Oc1cc(CN(C)C)ccn1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O HQJJNPLFWPONOJ-AULMGXOSSA-N 0.000 description 1
- QOMDMGYFGNODAG-NHIIVYHSSA-N CCc(cn1)cnc1O[C@H](CC1)CC[C@@H]1N(C([C@H]1CC[C@H](C)CC1)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)Cc2nc(O[C@H](CC3)CC[C@H]3N(C([C@H]3CC[C@H](C)CC3)=O)c3c(C(O)=O)[s]c(C#CC(C)(C)C)c3)ncc2)c1 Chemical compound CCc(cn1)cnc1O[C@H](CC1)CC[C@@H]1N(C([C@H]1CC[C@H](C)CC1)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)Cc2nc(O[C@H](CC3)CC[C@H]3N(C([C@H]3CC[C@H](C)CC3)=O)c3c(C(O)=O)[s]c(C#CC(C)(C)C)c3)ncc2)c1 QOMDMGYFGNODAG-NHIIVYHSSA-N 0.000 description 1
- FOEMIZSFFWGXHX-UHFFFAOYSA-N CSc1ncccn1 Chemical compound CSc1ncccn1 FOEMIZSFFWGXHX-UHFFFAOYSA-N 0.000 description 1
- DCVXXBSOALSOCT-ACRUOGEOSA-N C[C@@H](CCOc1cnccc1)N(C([C@H]1CC[C@H](C)CC1)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1 Chemical compound C[C@@H](CCOc1cnccc1)N(C([C@H]1CC[C@H](C)CC1)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1 DCVXXBSOALSOCT-ACRUOGEOSA-N 0.000 description 1
- JIMBKAVWHTWXQJ-UFYCRDLUSA-N C[C@@H](CCOc1ncccn1)N(C([C@H]1CC[C@H](C)CC1)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1 Chemical compound C[C@@H](CCOc1ncccn1)N(C([C@H]1CC[C@H](C)CC1)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1 JIMBKAVWHTWXQJ-UFYCRDLUSA-N 0.000 description 1
- CKHSTWDUMMKPEL-MEMLXQNLSA-N C[C@H](CC1)CC[C@@H]1C(N(C(CC1)CCN1S(c1cnccc1)(=O)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N(C(CC1)CCN1S(c1cnccc1)(=O)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O CKHSTWDUMMKPEL-MEMLXQNLSA-N 0.000 description 1
- ROHZXBGOWBVRHI-ACRUOGEOSA-N C[C@H](CC1)CC[C@@H]1C(N([C@@H](CC1)CN1S(c1cnccc1)(=O)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@@H](CC1)CN1S(c1cnccc1)(=O)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O ROHZXBGOWBVRHI-ACRUOGEOSA-N 0.000 description 1
- LVAVEGHVIHKCNJ-IFSQOONMSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1OC(C=CN1)=NC1=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1OC(C=CN1)=NC1=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O LVAVEGHVIHKCNJ-IFSQOONMSA-N 0.000 description 1
- COACHVJQVZURCG-IFSQOONMSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc(nn1)ccc1O)c1c(C(O)=O)[s]c(C#CC2(CCC2)C(F)(F)F)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc(nn1)ccc1O)c1c(C(O)=O)[s]c(C#CC2(CCC2)C(F)(F)F)c1)=O COACHVJQVZURCG-IFSQOONMSA-N 0.000 description 1
- HUEMGDNXEQTFAN-PBCKQTSCSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1c(CN(CC2)CC2N(C)C)ccnc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1c(CN(CC2)CC2N(C)C)ccnc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O HUEMGDNXEQTFAN-PBCKQTSCSA-N 0.000 description 1
- CDPLEDLRPNRMEH-QWZLJSJVSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1cc(CN(C)C)ccn1)c1c(C(O)=O)[s]c(C#CC2(CC2)C(F)(F)F)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1cc(CN(C)C)ccn1)c1c(C(O)=O)[s]c(C#CC2(CC2)C(F)(F)F)c1)=O CDPLEDLRPNRMEH-QWZLJSJVSA-N 0.000 description 1
- KVOUESFXZQCLLP-MVBYDDMTSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1cc(CN(C)C)cnc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1cc(CN(C)C)cnc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O KVOUESFXZQCLLP-MVBYDDMTSA-N 0.000 description 1
- DWVPQAZEQIOEDS-MUGGOUMZSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1nc(CN2CCOCC2)ccc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1nc(CN2CCOCC2)ccc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O DWVPQAZEQIOEDS-MUGGOUMZSA-N 0.000 description 1
- UUCQLJNFHZYTON-MVBYDDMTSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1nccc(CN(C)C)c1)c1c(C(O)=O)[s]c(C#CC2(CCC2)C(F)(F)F)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1nccc(CN(C)C)c1)c1c(C(O)=O)[s]c(C#CC2(CCC2)C(F)(F)F)c1)=O UUCQLJNFHZYTON-MVBYDDMTSA-N 0.000 description 1
- SXKJFTGLURDMII-CHDDOINTSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1ncncc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1ncncc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O SXKJFTGLURDMII-CHDDOINTSA-N 0.000 description 1
- HWFPVIWQOUDLIC-REODPECZSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1S/C(/NN)=C/N)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1S/C(/NN)=C/N)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O HWFPVIWQOUDLIC-REODPECZSA-N 0.000 description 1
- ZGGSKCQZMYXDOB-UBBSCCEASA-O C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Sc1[nH+][nH]cn1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Sc1[nH+][nH]cn1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O ZGGSKCQZMYXDOB-UBBSCCEASA-O 0.000 description 1
- OYMKPOCENOJCMQ-KBQPQWKXSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Sc1ccccn1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Sc1ccccn1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O OYMKPOCENOJCMQ-KBQPQWKXSA-N 0.000 description 1
- JCGVRQXBRNGKFH-YSXIEMCBSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Sc1nnc(C)[o]1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Sc1nnc(C)[o]1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O JCGVRQXBRNGKFH-YSXIEMCBSA-N 0.000 description 1
- GSRQLELLPZXJEL-AGJYPBCPSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@H]1Oc1cccnc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@H]1Oc1cccnc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O GSRQLELLPZXJEL-AGJYPBCPSA-N 0.000 description 1
- HUDMIVJEYSDLFN-SVRSMAFJSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@H]1Oc1cncnc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@H]1Oc1cncnc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O HUDMIVJEYSDLFN-SVRSMAFJSA-N 0.000 description 1
- HSSVKHZTWZIETE-PVPVSOICSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@H]1Sc1ncc[s]1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@H]1Sc1ncc[s]1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O HSSVKHZTWZIETE-PVPVSOICSA-N 0.000 description 1
- HYGZCHJAYASXHA-YDHSSHFGSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CCOc1ccccn1)OC1=O)c2c1[s]c(C#CC(C)(C)C)c2)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CCOc1ccccn1)OC1=O)c2c1[s]c(C#CC(C)(C)C)c2)=O HYGZCHJAYASXHA-YDHSSHFGSA-N 0.000 description 1
- ICVBBGCKGONZJH-HDJSIYSDSA-N C[C@H](CC1)CC[C@@H]1[IH](N(C)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1[IH](N(C)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O ICVBBGCKGONZJH-HDJSIYSDSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22736709P | 2009-07-21 | 2009-07-21 | |
| US61/227,367 | 2009-07-21 | ||
| US24091109P | 2009-09-09 | 2009-09-09 | |
| US61/240,911 | 2009-09-09 | ||
| US35946610P | 2010-06-29 | 2010-06-29 | |
| US61/359,466 | 2010-06-29 | ||
| PCT/US2010/042394 WO2011011303A1 (en) | 2009-07-21 | 2010-07-19 | Inhibitors of flaviviridae viruses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015160807A Division JP2015205940A (ja) | 2009-07-21 | 2015-08-18 | フラビウイルス科ウイルスの阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012533630A JP2012533630A (ja) | 2012-12-27 |
| JP2012533630A5 true JP2012533630A5 (enExample) | 2015-02-26 |
| JP5841531B2 JP5841531B2 (ja) | 2016-01-13 |
Family
ID=42711860
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012521700A Expired - Fee Related JP5841531B2 (ja) | 2009-07-21 | 2010-07-19 | フラビウイルス科ウイルスの阻害剤 |
| JP2015160807A Withdrawn JP2015205940A (ja) | 2009-07-21 | 2015-08-18 | フラビウイルス科ウイルスの阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015160807A Withdrawn JP2015205940A (ja) | 2009-07-21 | 2015-08-18 | フラビウイルス科ウイルスの阻害剤 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8569302B2 (enExample) |
| EP (1) | EP2475657B1 (enExample) |
| JP (2) | JP5841531B2 (enExample) |
| KR (1) | KR20120051022A (enExample) |
| CN (1) | CN102471327A (enExample) |
| AP (1) | AP3409A (enExample) |
| AR (1) | AR077765A1 (enExample) |
| AU (1) | AU2010276441B2 (enExample) |
| CA (1) | CA2767088C (enExample) |
| CL (1) | CL2012000147A1 (enExample) |
| CO (1) | CO6491049A2 (enExample) |
| CR (1) | CR20120081A (enExample) |
| DK (1) | DK2475657T3 (enExample) |
| EA (1) | EA020816B1 (enExample) |
| EC (1) | ECSP12011684A (enExample) |
| ES (1) | ES2427342T3 (enExample) |
| IL (1) | IL217243A (enExample) |
| MX (1) | MX2012000959A (enExample) |
| NZ (1) | NZ597528A (enExample) |
| PE (1) | PE20120666A1 (enExample) |
| SG (1) | SG177709A1 (enExample) |
| TW (1) | TW201116525A (enExample) |
| UY (1) | UY32793A (enExample) |
| WO (1) | WO2011011303A1 (enExample) |
| ZA (1) | ZA201200940B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201116525A (en) * | 2009-07-21 | 2011-05-16 | Gilead Sciences Inc | Inhibitors of flaviviridae viruses |
| KR20120081123A (ko) | 2009-09-09 | 2012-07-18 | 길리애드 사이언시즈, 인코포레이티드 | 플라비비리대 바이러스의 억제제 |
| WO2011035250A1 (en) | 2009-09-21 | 2011-03-24 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs |
| KR20120123678A (ko) | 2010-01-15 | 2012-11-09 | 길리애드 사이언시즈, 인코포레이티드 | 플라비비리다에 바이러스의 억제제 |
| PE20130281A1 (es) | 2010-01-15 | 2013-03-08 | Gilead Sciences Inc | Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae |
| EP2585447A2 (en) * | 2010-06-28 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
| ES2524356T3 (es) | 2010-07-22 | 2014-12-05 | Gilead Sciences, Inc. | Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae |
| AU2011281546B2 (en) | 2010-07-22 | 2014-07-10 | Novartis Ag | 2,3,5-trisubstituted thiophene compounds and uses thereof |
| EP2734515B1 (en) | 2011-07-13 | 2015-11-04 | Gilead Sciences, Inc. | Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses |
| BR112014032538A2 (pt) | 2012-06-26 | 2017-06-27 | Bayer Pharma AG | n-[4-(quinolin-4-ilóxi)ciclo-hexil(metil)] (hetero)arilcarboxamidas como antagonistas do receptor de andrógeno, produção e uso das mesmas como produtos medicinais |
| US8927741B2 (en) | 2012-08-17 | 2015-01-06 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
| US8759544B2 (en) | 2012-08-17 | 2014-06-24 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
| US8841340B2 (en) | 2012-08-17 | 2014-09-23 | Gilead Sciences, Inc. | Solid forms of an antiviral compound |
| CN102964295B (zh) * | 2012-12-17 | 2014-08-20 | 寿光富康制药有限公司 | 一种2-取代-4-（哌啶基甲基）吡啶的制备方法 |
| EP2762124A1 (en) * | 2013-01-31 | 2014-08-06 | IP Gesellschaft für Management mbH | Packaging comprising administration units of polymorphs, amorphous forms or solvates |
| US9492438B2 (en) * | 2014-07-25 | 2016-11-15 | Bette Pollard | Amphiphilic pyridinum compounds to treat epilepsy and other disorders of the nervous system |
| TWI740546B (zh) | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| IL296496B2 (en) | 2014-12-26 | 2024-10-01 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| HRP20220355T1 (hr) | 2015-09-16 | 2022-05-13 | Gilead Sciences, Inc. | Postupci za liječenje infekcija coronaviridae |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP4483875A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| HRP20220479T1 (hr) | 2016-06-01 | 2022-05-27 | Athira Pharma, Inc. | Spojevi |
| CN116036112A (zh) | 2017-03-14 | 2023-05-02 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
| WO2018204198A1 (en) | 2017-05-01 | 2018-11-08 | Gilead Sciences, Inc. | Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| EP3641762B1 (en) | 2017-06-20 | 2026-02-18 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| EP4512475A3 (en) | 2017-07-11 | 2025-05-14 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| AU2021214911A1 (en) | 2020-01-27 | 2022-07-21 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
| CN118994170A (zh) | 2020-03-12 | 2024-11-22 | 吉利德科学公司 | 制备1'-氰基核苷的方法 |
| EP4132651B1 (en) | 2020-04-06 | 2026-03-18 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| ES3041698T3 (en) | 2020-05-29 | 2025-11-13 | Gilead Sciences Inc | Remdesivir for the treatment of viral infections |
| CA3187821A1 (en) | 2020-06-24 | 2021-12-30 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
| WO2022013684A1 (en) | 2020-07-11 | 2022-01-20 | Pfizer Inc. | Antiviral heteroaryl ketone derivatives |
| WO2022047065A2 (en) | 2020-08-27 | 2022-03-03 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| TW202525810A (zh) | 2022-03-02 | 2025-07-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861421A (en) * | 1995-12-21 | 1999-01-19 | Smithkline Beecham Corporation | 4,4-(disubstituted) cyclohexan-1-one monomers and related compounds |
| US20050119332A1 (en) * | 1998-03-12 | 2005-06-02 | Lone Jeppesen | Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases) |
| US20020002199A1 (en) * | 1998-03-12 | 2002-01-03 | Lone Jeppesen | Modulators of protein tyrosine phosphatases (ptpases) |
| CA2449999C (en) | 2001-06-11 | 2012-07-31 | Shire Biochem Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| AU2002344854B2 (en) * | 2001-06-11 | 2008-11-06 | Vertex Pharmaceuticals (Canada) Incorporated | Thiophene derivatives as antiviral agents for flavivirus infection |
| CN100413861C (zh) * | 2002-12-10 | 2008-08-27 | 维勒凯姆制药股份有限公司 | 用于治疗或预防黄病毒感染的化合物 |
| MXPA05006196A (es) | 2002-12-10 | 2006-01-27 | Virochem Pharma Inc | Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus. |
| DE10359791A1 (de) * | 2003-12-19 | 2005-07-21 | Bayer Healthcare Ag | Substituierte Thiophene |
| AR047894A1 (es) * | 2004-02-25 | 2006-03-01 | Wyeth Corp | Derivados de tiofeno como inhibidores de la proteina tirosina fosfatasa 1b (ptpasa 1b); metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por ptpasa 1b |
| CN1989131A (zh) * | 2004-03-30 | 2007-06-27 | 希龙公司 | 取代的噻吩衍生物用作抗癌药 |
| DE102004061746A1 (de) * | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Alkinyl-substituierte Thiophene |
| DE102005028077A1 (de) | 2004-12-22 | 2006-07-13 | Aicuris Gmbh & Co. Kg | Alkinyl-substituierte Thiophene |
| CN101218224B (zh) * | 2005-05-13 | 2013-05-08 | Viro化学制药公司 | 治疗或预防黄病毒感染的组合物和方法 |
| CN101384605A (zh) * | 2006-02-15 | 2009-03-11 | 塞诺菲-安万特股份有限公司 | 新的氨基醇取代的芳基噻吩并嘧啶酮、其制备方法以及其作为药物的用途 |
| PT2104674E (pt) * | 2006-11-15 | 2013-07-26 | Virochem Pharma Inc | Análogos de tiofeno para o tratamento ou prevenção de infeções por flavivírus |
| WO2008059042A1 (en) * | 2006-11-17 | 2008-05-22 | Smithkline Beecham Corporation | 2-carboxy thiophene derivatives as anti viral agents |
| EP2774927A1 (en) | 2008-12-03 | 2014-09-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
| TW201116525A (en) * | 2009-07-21 | 2011-05-16 | Gilead Sciences Inc | Inhibitors of flaviviridae viruses |
| KR20120081123A (ko) * | 2009-09-09 | 2012-07-18 | 길리애드 사이언시즈, 인코포레이티드 | 플라비비리대 바이러스의 억제제 |
| JP2013512247A (ja) | 2009-11-25 | 2013-04-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染症の治療または予防のための５−アルキニル−チオフェン−２−カルボン酸誘導体およびそれらの使用 |
| PE20130281A1 (es) | 2010-01-15 | 2013-03-08 | Gilead Sciences Inc | Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae |
| KR20120123678A (ko) * | 2010-01-15 | 2012-11-09 | 길리애드 사이언시즈, 인코포레이티드 | 플라비비리다에 바이러스의 억제제 |
| EP2585447A2 (en) | 2010-06-28 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
-
2010
- 2010-07-19 TW TW099123657A patent/TW201116525A/zh unknown
- 2010-07-19 ES ES10735402T patent/ES2427342T3/es active Active
- 2010-07-19 PE PE2012000069A patent/PE20120666A1/es not_active Application Discontinuation
- 2010-07-19 EA EA201290053A patent/EA020816B1/ru not_active IP Right Cessation
- 2010-07-19 AU AU2010276441A patent/AU2010276441B2/en not_active Ceased
- 2010-07-19 CA CA2767088A patent/CA2767088C/en not_active Expired - Fee Related
- 2010-07-19 JP JP2012521700A patent/JP5841531B2/ja not_active Expired - Fee Related
- 2010-07-19 MX MX2012000959A patent/MX2012000959A/es active IP Right Grant
- 2010-07-19 WO PCT/US2010/042394 patent/WO2011011303A1/en not_active Ceased
- 2010-07-19 DK DK10735402.9T patent/DK2475657T3/da active
- 2010-07-19 AR ARP100102629A patent/AR077765A1/es unknown
- 2010-07-19 CN CN2010800328463A patent/CN102471327A/zh active Pending
- 2010-07-19 AP AP2012006085A patent/AP3409A/xx active
- 2010-07-19 KR KR1020127004379A patent/KR20120051022A/ko not_active Withdrawn
- 2010-07-19 UY UY0001032793A patent/UY32793A/es not_active Application Discontinuation
- 2010-07-19 SG SG2012004115A patent/SG177709A1/en unknown
- 2010-07-19 NZ NZ597528A patent/NZ597528A/en not_active IP Right Cessation
- 2010-07-19 EP EP10735402.9A patent/EP2475657B1/en active Active
- 2010-07-19 US US12/838,684 patent/US8569302B2/en active Active
-
2011
- 2011-12-28 IL IL217243A patent/IL217243A/en not_active IP Right Cessation
-
2012
- 2012-01-17 CO CO12006267A patent/CO6491049A2/es active IP Right Grant
- 2012-01-19 CL CL2012000147A patent/CL2012000147A1/es unknown
- 2012-02-08 ZA ZA2012/00940A patent/ZA201200940B/en unknown
- 2012-02-16 CR CR20120081A patent/CR20120081A/es unknown
- 2012-02-16 EC ECSP12011684 patent/ECSP12011684A/es unknown
-
2013
- 2013-09-25 US US14/037,296 patent/US20140030223A1/en not_active Abandoned
-
2015
- 2015-08-18 JP JP2015160807A patent/JP2015205940A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013517286A5 (enExample) | ||
| US10738035B2 (en) | Hepatitis B antiviral agents | |
| JP5898067B2 (ja) | がん及び非新生物性状態の治療方法 | |
| KR102279999B1 (ko) | 선택적 에스트로겐 수용체 분해제로서의 벤조티오펜 유도체 및 그의 조성물 | |
| ES2572803T3 (es) | Estimuladores de GCs | |
| JP2020527588A5 (enExample) | ||
| HRP20140370T1 (hr) | 1'-supstituirani-karba-nukleozid prolijekovi za antivirusni tretman | |
| JP2014520822A5 (enExample) | ||
| JP2012519691A5 (enExample) | ||
| RU2016122908A (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| JP2016503800A5 (enExample) | ||
| JP2019527731A (ja) | Ｈｂｖ感染の治療のための新規治療薬 | |
| JP2013517291A5 (enExample) | ||
| JP2010510233A5 (enExample) | ||
| JP2020507582A5 (enExample) | ||
| JP2010527373A5 (enExample) | ||
| JP2011520906A5 (enExample) | ||
| JP2015512860A5 (enExample) | ||
| JP2010510234A5 (enExample) | ||
| JP2012528166A5 (enExample) | ||
| JP2011518835A5 (enExample) | ||
| JP2013507439A5 (enExample) | ||
| JP2008514732A5 (enExample) | ||
| JP2011006480A5 (enExample) | ||
| JP2013538230A5 (enExample) |